JacobStephenThomasMD

Oncology • Los Angeles, CA

Head & Neck Cancer

Assistant Clinical Professor of Medicine

Join to view full profile

Dr. Thomas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thomas' full profile

Already have an account?

Office
1441 Eastlake Ave
Los Angeles, CA 90089
Phone+1 323-865-3105

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2015 - 2018
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2012 - 2015
University of Illinois College of MedicineClass of 2012

Certifications & Licensure

CA State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Start of enrollment: 2018 Aug 21
Completed
Phase 1

Publications & Presentations

PubMed

First-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors.
Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas, Claire Livings, Elena Garralda
Clinical Cancer Research. 2025-01-23
Real-World Incidence of Anaplastic Lymphoma Kinase alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.
Darin Poei, Sana Ali, Jacob S Thomas, Jorge J Nieva, Robert C Hsu
Cancer Research Communications. 2025-01-14
Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis acr...
Ryan Cooper, Dhruv Ramaswami, Jacob S Thomas, Jorge J Nieva, Robert Hsu
Discover Oncology. 2024-11-21

Press Mentions

Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
Data from Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients with Advanced Solid TumorsNovember 7th, 2019
Hoag Hospital Clinical Investigator Discusses the Importance of Clinical Trials in the CommunityAugust 30th, 2019